Abstract
The insulin-like growth factors (IGFs) acting via the type I IGF receptor (IGF-1R) regulate cancer cell proliferation, survival, metabolism and metastasis. Drugs targeting the IGF-1R are being tested in human clinical trials for cancer therapy and it seems likely that this class of drugs could be approved soon. Recent data suggests that insulin receptor, which is closely related to IGF-1R, should also be targeted to maximally inhibit the system. Furthermore, biomarkers that identify patients whose tumors are driven by IGF-1R and biomarkers that allow monitoring or prediction of response are needed. This article reviews the different drugs against IGF-1R that are being tested and how this receptor pathway can be optimally targeted for cancer therapy with an emphasis on breast cancer therapy.
Keywords: Breast cancer, targeted therapy, insulin-like growth factors, IGF-1R, antibodies, small molecule inhibitors, clinical trials
Current Drug Targets
Title: Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Volume: 11 Issue: 9
Author(s): Deepali Sachdev
Affiliation:
Keywords: Breast cancer, targeted therapy, insulin-like growth factors, IGF-1R, antibodies, small molecule inhibitors, clinical trials
Abstract: The insulin-like growth factors (IGFs) acting via the type I IGF receptor (IGF-1R) regulate cancer cell proliferation, survival, metabolism and metastasis. Drugs targeting the IGF-1R are being tested in human clinical trials for cancer therapy and it seems likely that this class of drugs could be approved soon. Recent data suggests that insulin receptor, which is closely related to IGF-1R, should also be targeted to maximally inhibit the system. Furthermore, biomarkers that identify patients whose tumors are driven by IGF-1R and biomarkers that allow monitoring or prediction of response are needed. This article reviews the different drugs against IGF-1R that are being tested and how this receptor pathway can be optimally targeted for cancer therapy with an emphasis on breast cancer therapy.
Export Options
About this article
Cite this article as:
Sachdev Deepali, Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy, Current Drug Targets 2010; 11 (9) . https://dx.doi.org/10.2174/138945010792006816
DOI https://dx.doi.org/10.2174/138945010792006816 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Molecular Probes for Malignant Melanoma Imaging
Current Pharmaceutical Biotechnology Recent Advances in Selective Estrogen Receptor Modulators for Breast Cancer
Mini-Reviews in Medicinal Chemistry EZN-2208 (PEG-SN38), A 40 kDa Polyethylene Glycol (PEG) Conjugate, As an Anticancer Agent: Review of Preclinical and Clinical Data
Current Bioactive Compounds Poly(ADP-ribosylation) and Neoplastic Transformation: Effect of PARP Inhibitors
Current Pharmaceutical Biotechnology Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Taming Oncogenic Signaling at Protein Interfaces: Challenges and Opportunities
Current Topics in Medicinal Chemistry The Cellular Pharmacokinetics of HIV Protease Inhibitors: Current Knowledge and Future Perspectives
Current Drug Metabolism New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways
Current Cancer Therapy Reviews Design, Synthesis, and Biological Evaluation of Novel C5-Modified Pyrimidine Ribofuranonucleosides as Potential Antitumor or/and Antiviral Agents
Medicinal Chemistry Tumor Necrosis Factor-α-Mediated Pulmonary Endothelial Barrier Dysfunction
Current Respiratory Medicine Reviews mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process
Mini-Reviews in Medicinal Chemistry ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry QSPR in Oral Bioavailability: Specificity or Integrality?
Mini-Reviews in Medicinal Chemistry Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine